FDA Approves DECNUPAZTM (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options DECNUPAZ is the first and only antibody-drug conjugate (ADC) approved for blastic plasmacytoid dendritic cell neoplasm (BPDCN) that is initiated in an outpatient setting DECNUPAZ marks AbbVies first ADC approved for blood cancer NORTH CHICAGO, Ill., May 27, 2026 /PRNewswire/ Click here to view original post Click Here to Publish/Feature Your Company or Product News with Biotech Networks To view or add a comment, sign in We've achieved 82% stable disease per RECIST, with 9 of 11 evaluable patients achieving stable disease, including one patient maintaining stable disease for over 15 months and another for 12 months
They reduce hunger
Healthcare professionals will consider several factors before recommending this combination, including the patient's complete medication profile, existing medical conditions, treatment goals, and previous responses to either medication
Wait 3 months after receiving a blood transfusion (unless it was your own "autologous" blood), non-sterile needle stick or exposure to someone else's blood
Based in the USA Physician backed & formulated
